IllustrativeuniQure shares surge as FDA stance appears to reopen a near-term filing path for AMT-130
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Shares of uniQure have increased after the FDA's stance seemed to allow for a potential near-term filing for AMT-130. This development suggests a possible shift in the regulatory path for the treatment. The change in the FDA's stance has apparently created a new opportunity for uniQure to move forward with AMT-130.